Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;133(7):1029-1037.
doi: 10.1038/s41416-025-03123-0. Epub 2025 Jul 23.

Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy

Affiliations

Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy

Ki-Yong An et al. Br J Cancer. 2025 Oct.

Abstract

Background: The effects of exercise on cancer outcomes may differ depending on its positioning within different cancer treatment combinations. We examined whether the associations between physical activity (PA) and cancer outcomes varied by cancer treatment modality or timing of PA.

Methods: We conducted a secondary analysis of the Prostate Cancer Cohort Study consisting of 830 men in Alberta, Canada with newly diagnosed prostate cancer. Lifetime prediagnosis PA was assessed by an in-person interview shortly after diagnosis whereas postdiagnosis PA was assessed at 2-3 year intervals by an in-person interview (first follow-up) or self-report (second and third follow-ups). Cox proportional hazards regression models were used to test interactions between PA and treatment modalities for disease-free survival, overall survival, and prostate cancer-specific disease-free survival.

Results: Postdiagnosis vigorous PA significantly interacted with surgery (p < 0.001) and radiotherapy (p = 0.003). Specifically, patients who had surgery experienced a 61% lower likelihood of a disease-free survival event if they engaged in any versus no postdiagnosis vigorous PA (HR = 0.39, 95% CI = 0.27-0.57). Conversely, patients who received radiotherapy did not experience any benefit from postdiagnosis vigorous PA (HR = 1.14, 95% CI = 0.88-1.47).

Conclusions: The role of PA as a treatment for prostate cancer may depend on its combination and sequencing with other treatments.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Ethics approval was obtained from the former Alberta Cancer Board (ACB) and the University of Calgary for the case-control study, and from the Alberta Cancer Research Ethics Board and the Conjoint Health Research Ethics Board at the University of Calgary for the cohort follow-up study. All participants provided written informed consent for the cohort study. This study was performed in accordance with the Declaration of Helsinki.

Comment in

References

    1. Courneya KS, Friedenreich CM. Designing, analyzing, and interpreting observational studies of physical activity and cancer outcomes from a clinical oncology perspective. Front Oncol. 2023;13:1098278. - PMC - PubMed
    1. Courneya KS, Booth, CM. Exercise as a cancer treatment: a clinical oncology framework for exercise oncology research. Front Oncol. 2022;12:957135. - PMC - PubMed
    1. Courneya KS, McNeely ML, Booth CM, Friedenreich CM. An integrated framework for the study of exercise across the postdiagnosis cancer continuum. Front Oncol. 2024;14:1432899. - PMC - PubMed
    1. Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, et al. Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy. JCO Precis Oncol. 2022;6:e2000368. - PMC - PubMed
    1. Topham JT, O’Callaghan CJ, Feilotter H, Kennecke HF, Lee YS, Li W, et al. Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. J Clin Oncol. 2023;41:485–96. JCO2200364. - PMC - PubMed